دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Every Country, Every Family: Time to Act for Group B Streptococcal Disease Worldwide
Joy E Lawn, Jaya Chandna, Proma Paul, Mark Jit, Caroline Trotter, Philipp Lambach, Ajoke Sobanjo Ter-Meulen
doi : 10.1093/cid/ciab859
Clinical Infectious Diseases, Volume 74, Issue Supplement_1, 15 January 2022, Pages S1–S4
The global burden of Group B Streptococcus (GBS) was estimated for 2015 prompting inclusion of GBS as a priority in the Global Meningitis Roadmap. New estimates for the year 2020 and a WHO report analysing the full value of GBS maternal vaccines has been launched to advance evidence based decision making for multiple stakeholders. In this first of a 10-article supplement, we discuss the following (1) gaps in evidence and action, (2) new evidence in this supplement, and (3) what actions can be taken now and key research gaps ahead. We call for investment in the research pipeline, notably description, development, and delivery, in order to accelerate progress and address the large burden of GBS for every family in every country.
South African Children: A Matched Cohort Study of Neurodevelopmental Impairment in Survivors of Invasive Group B Streptococcus Disease Aged 5 to 8 Years
Lois M Harden, Shannon Leahy, Sanjay G Lala, Proma Paul, Jaya Chandna, Sarah Lowick, Sibongile Mbatha, Tamara Jaye, Barbara Laughton, Azra Ghoor, Pamela Sithole, Jacqueline Msayi, Ntombifuthi Kumalo, Tshepiso N Msibi, Shabir A Madhi, Joy E Lawn, Ziyaad Dangor
doi : 10.1093/cid/ciab814
Clinical Infectious Diseases, Volume 74, Issue Supplement_1, 15 January 2022, Pages S5–S13
Invasive group B Streptococcus (iGBS) sepsis and meningitis are important causes of child mortality, but studies on neurodevelopmental impairment (NDI) after iGBS are limited. Using Griffiths Mental Development Scales–Extended Revised (GMDS-ER), we described NDI in iGBS survivors and non-iGBS children from South Africa, as part of a 5-country study.
Short- and Long-term Outcomes of Group B Streptococcus Invasive Disease in Mozambican Children: Results of a Matched Cohort and Retrospective Observational Study and Implications for Future Vaccine Introduction
Justina Bramugy, Humberto Mucasse, Sergio Massora, Pio Vitorino, Céline Aerts, Inacio Mandomando, Proma Paul, Jaya Chandna, Farah Seedat, Joy E Lawn, Azucena Bardaj?, Quique Bassat
doi : 10.1093/cid/ciab793
Clinical Infectious Diseases, Volume 74, Issue Supplement_1, 15 January 2022, Pages S14–S23
Invasive group B Streptococcus disease (iGBS) in infancy, including meningitis or sepsis, carries a high risk of mortality and neurodevelopmental impairment (NDI). We present data on iGBS from 2 decades of surveillance in Manhiça, Mozambique, with a focus on NDI.
South Indian Children’s Neurodevelopmental Outcomes After Group B Streptococcus Invasive Disease: A Matched-Cohort Study
Hima B John, Asha Arumugam, Mohana Priya, Nandhini Murugesan, Nandhini Rajendraprasad, Grace Rebekah, Proma Paul, Jaya Chandna, Joy E Lawn, Sridhar Santhanam
doi : 10.1093/cid/ciab792
Clinical Infectious Diseases, Volume 74, Issue Supplement_1, 15 January 2022, Pages S24–S34
This study is part of a multicountry matched-cohort study designed to estimate the risk of long-term neurodevelopmental impairment (NDI) of children exposed to invasive group B Streptococcus (iGBS). The specific objective of this paper is to compare NDI across domains of iGBS survivors with a matched non iGBS group in our population.
Emotional and Behavioral Outcomes in Childhood for Survivors of Invasive Group B Streptococcus Disease in Infancy: Findings From 5 Low- and Middle-Income Countries
Jaya Chandna, Wan-Hsin Liu, Ziyaad Dangor, Shannon Leahy, Santhanam Sridhar, Hima B John, Humberto Mucasse, Quique Bassat, Azucena Bardaji, Amina Abubakar, Carophine Nasambu, Charles R Newton, Clara S?nchez Yanotti, Romina Libster, Kate Milner, Proma Paul, Joy E Lawn, GBS Low and Middle income Collaborative Group for Long-term Outcomes group
doi : 10.1093/cid/ciab821
Clinical Infectious Diseases, Volume 74, Issue Supplement_1, 15 January 2022, Pages S35–S43
Survivors of invasive group B Streptococcus (iGBS) disease, notably meningitis, are at increased risk of neurodevelopmental impairment. However, the limited studies to date have a median follow-up to 18 months and have mainly focused on moderate or severe neurodevelopmental impairment, with no previous studies on emotional-behavioral problems among iGBS survivors.
Prematurity Modifies the Risk of Long-term Neurodevelopmental Impairments After Invasive Group B Streptococcus Infections During Infancy in Denmark and the Netherlands
Erzsébet Horv?th-Puh?, Linde Snoek, Merel N van Kassel, Bronner P Gonçalves, Jaya Chandna, Simon R Procter, Diederik van de Beek, Brechje de Gier, Arie van der Ende, Henrik T S?rensen, Joy E Lawn, Merijn W Bijlsma, GBS Danish and Dutch Collaborative Group for Long-term Outcomes
doi : 10.1093/cid/ciab774
Clinical Infectious Diseases, Volume 74, Issue Supplement_1, 15 January 2022, Pages S44–S53
Preterm birth and neonatal infections are both associated with mortality and long-term neurodevelopmental impairments (NDIs). We examined whether the effect of invasive group B Streptococcus disease (iGBS) on mortality and long-term NDI differs for preterm and term infants, and whether co-occurrence of iGBS and prematurity leads to worse outcome.
Sex Differences in Long-term Outcomes After Group B Streptococcal Infections During Infancy in Denmark and the Netherlands: National Cohort Studies of Neurodevelopmental Impairments and Mortality
Merel N van Kassel, Bronner P Gonçalves, Linde Snoek, Henrik T S?rensen, Merijn W Bijlsma, Joy E Lawn, Erzsébet Horv?th-Puh?, GBS Danish and Dutch Collaborative Group for Long-Term Outcomes
doi : 10.1093/cid/ciab822
Clinical Infectious Diseases, Volume 74, Issue Supplement_1, 15 January 2022, Pages S54–S63
Male infants have a higher incidence of invasive group B Streptococcus disease (iGBS) compared with female infants; however, data on sex differences in mortality and long-term outcomes after iGBS are lacking. We assessed whether a child’s sex influences the effects of iGBS on mortality and risk of neurodevelopmental impairments (NDIs).
Quantifying the Acute Care Costs of Neonatal Bacterial Sepsis and Meningitis in Mozambique and South Africa
Céline Aerts, Shannon Leahy, Humberto Mucasse, Sanjay Lala, Justina Bramugy, Cally J Tann, Shabir A Madhi, Azucena Bardaj?, Quique Bassat, Ziyaad Dangor, Joy E Lawn, Mark Jit, Simon R Procter
doi : 10.1093/cid/ciab815
Clinical Infectious Diseases, Volume 74, Issue Supplement_1, 15 January 2022, Pages S64–S69
Sepsis and meningitis are among the leading causes of neonatal deaths in sub-Saharan Africa (SSA). Neonatal sepsis caused ~400 000 deaths globally in 2015, half occurring in Africa. Despite this, there are few published data on the acute costs of neonatal sepsis or meningitis, with none in SSA.
A Financial and Global Demand Analysis to Inform Decisions for Funding and Clinical Development of Group B Streptococcus Vaccines for Pregnant Women
Stefano Malvolti, Clint Pecenka, Carsten F Mantel, Melissa Malhame, Philipp Lambach
doi : 10.1093/cid/ciab782
Clinical Infectious Diseases, Volume 74, Issue Supplement_1, 15 January 2022, Pages S70–S79
Despite group B Streptococcus (GBS) being a leading cause of maternal and infant morbidity and mortality, no vaccine is currently available. To inform vaccine developers, countries, and funders, we analyzed the key factors likely to influence the demand for a GBS vaccine and the long-term financial sustainability for a vaccine developer.
Stakeholder Perceptions About Group B Streptococcus Disease and Potential for Maternal Vaccination in Low- and Middle-Income Countries
Carsten Mantel, Thomas Cherian, Melissa Ko, Stefano Malvolti, Elizabeth Mason, Michelle Giles, Philipp Lambach
doi : 10.1093/cid/ciab794
Clinical Infectious Diseases, Volume 74, Issue Supplement_1, 15 January 2022, Pages S80–S87
To inform the World Health Organization’s full value of vaccine assessment for group B Streptococcus (GBS) vaccines, a rapid literature appraisal was conducted to inform the operationalization of maternal GBS vaccination. We found limited published information on stakeholder perceptions of the public health importance of GBS disease and vaccination, and we therefore undertook a multicountry survey.
A Link Between Obesity and Coronavirus Disease 2019
doi : 10.1093/cid/ciac016
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Pages i–ii
Tracing People Living With Human Immunodeficiency Virus Who Are Lost to Follow-up at Antiretroviral Therapy Programs in Southern Africa: A Sampling-Based Cohort Study in 6 Countries
Marie Ballif, Benedikt Christ, Nanina Anderegg, Frédérique Chammartin, Josephine Muhairwe, Laura Jefferys, Jonas Hector, Janneke van Dijk, Michael J Vinikoor, Monique van Lettow, Cleophas Chimbetete, Sam J Phiri, Dorina Onoya, Matthew P Fox, Matthias Egger International epidemiology Databases to Evaluate AIDS (IeDEA)
doi : 10.1093/cid/ciab428
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Pages 171–179
Attrition threatens the success of antiretroviral therapy (ART). In this cohort study, we examined outcomes of people living with human immunodeficiency virus (PLHIV) who were lost to follow-up (LTFU) during 2014–2017 at ART programs in Southern Africa.
Efficacy, Safety and Tolerability of Pyronaridine-artesunate in Asymptomatic Malaria-infected Individuals: a Randomized Controlled Trial
Edgard D Dabira, Sebastian Hachizovu, Bakary Conteh, Alieu Mendy, Haddy Nyang, Bolarinde Lawal, Mamadou Ousmane Ndiath, Joyce M Mulenga, Sydney Mwanza, Isabelle Borghini-Fuhrer, Sarah Arbe-Barnes, Robert Miller, Jangsik Shin, Stephan Duparc, Umberto D’Alessandro, Christine Manyando, Jane Achan
doi : 10.1093/cid/ciab425
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Pages 180–188
Pyronaridine-artesunate (PA) is a registered artemisinin-based combination therapy, potentially useful for mass drug administration campaigns. However, further data are needed to evaluate its efficacy, safety and tolerability as full or incomplete treatment in asymptomatic Plasmodium falciparum-infected individuals.
Pertussis Immunization During Pregnancy: Assessment of the Role of Maternal Antibodies on Immune Responses in Term and Preterm-Born Infants
Kirsten Maertens, Marjolein R P Orije, Sereina A Herzog, Ludo M Mahieu, Niel Hens, Pierre Van Damme, Elke Leuridan
doi : 10.1093/cid/ciab424
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Pages 189–198
Limited data exist on the impact of maternal tetanus, diphtheria, acellular pertussis (Tdap) vaccination for preterm born infants. We report its effect at birth and on antibody-mediated immune responses to a DTaP-IPV-HB-PRP~T vaccine in preterm compared with term infants.
Role of Epithelial–Endothelial Cell Interaction in the Pathogenesis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
Kenrie Pui-Yan Hui, Man-Chun Cheung, Ka-Ling Lai, Ka-Chun Ng, John Chi-Wang Ho, Malik Peiris, John Malcolm Nicholls, Michael Chi-Wai Chan
doi : 10.1093/cid/ciab406
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Pages 199–209
The coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to threaten public health globally. Patients with severe COVID-19 disease progress to acute respiratory distress syndrome, with respiratory and multiple organ failure. It is believed that dysregulated production of proinflammatory cytokines and endothelial dysfunction contribute to the pathogenesis of severe diseases. However, the mechanisms of SARS-CoV-2 pathogenesis and the role of endothelial cells are poorly understood.
Cost-Effectiveness of 1-Time Universal Screening for Chronic Hepatitis B Infection in Adults in the United States
Mehlika Toy, David Hutton, Aaron M Harris, Noele Nelson, Joshua A Salomon, Samuel So
doi : 10.1093/cid/ciab405
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Pages 210–217
An estimated 862 000 to 2.4 million people have chronic hepatitis B infection (CHB). Hepatitis B screening is recommended for pregnant women and populations with increased CHB risk. However, diagnosis rates remain low, with only 33% of people with CHB aware of their infection. This study aimed to assess the cost-effectiveness of universal adult screening for CHB.
SARS-CoV-2 RNAemia Predicts Clinical Deterioration and Extrapulmonary Complications from COVID-19
Nikhil Ram-Mohan, David Kim, Elizabeth J Zudock, Marjan M Hashemi, Kristel C Tjandra, Angela J Rogers, Catherine A Blish, Kari C Nadeau, Jennifer A Newberry, James V Quinn, Ruth O’Hara, Euan Ashley, Hien Nguyen, Lingxia Jiang, Paul Hung, Andra L Blomkalns, Samuel Yang, Stanford COVID-19 Biobank Study Group
doi : 10.1093/cid/ciab394
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Pages 218–226
The determinants of coronavirus disease 2019 (COVID-19) disease severity and extrapulmonary complications (EPCs) are poorly understood. We characterized relationships between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNAemia and disease severity, clinical deterioration, and specific EPCs.
The Operational Feasibility of Vaccination Programs Targeting Influenza Risk Groups in the World Health Organization (WHO) African and South-East Asian Regions
Justin R Ortiz, Stephen L Yu, Amanda J Driscoll, Sarah R Williams, Joanie Robertson, Jui-Shan Hsu, Wilbur H Chen, Robin J Biellik, Samba Sow, Sonali Kochhar, Kathleen M Neuzil
doi : 10.1093/cid/ciab393
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Pages 227–236
Influenza vaccination is uncommon in low-resource settings. We evaluated aspects of operational feasibility of influenza vaccination programs targeting risk groups in the World Health Organization (WHO) African (AFR) and South-East Asian (SEAR) Regions.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Sequence Characteristics of Coronavirus Disease 2019 (COVID-19) Persistence and Reinfection
Manish C Choudhary, Charles R Crain, Xueting Qiu, William Hanage, Jonathan Z Li
doi : 10.1093/cid/ciab380
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Pages 237–245
Both severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection and persistent infection have been reported, but sequence characteristics in these scenarios have not been described. We assessed published cases of SARS-CoV-2 reinfection and persistence, characterizing the hallmarks of reinfecting sequences and the rate of viral evolution in persistent infection.
Menstrual Toxic Shock Syndrome: A French Nationwide Multicenter Retrospective Study
Damien Contou, Gwenhaël Colin, Brendan Travert, Sébastien Jochmans, Marie Conrad, Jean-Baptiste Lascarrou, Benoit Painvin, Alexis Ferré, David Schnell, Beatrice La Combe, Rémi Coudroy, Stephan Ehrmann, Jérôme Rambaud, Arnaud Wiedemann, Pierre Asfar, Pierre Kalfon, Emmanuel Guérot, Sébastien Préau, Laurent Argaud, Florence Daviet, Jean Dellamonica, Audrey Dupont, Muriel Fartoukh, Toufik Kamel, Gaëtan Béduneau, Florence Canouï-Poitrine, Emmanuelle Boutin, Gérard Lina, Armand Mekontso Dessap, Anne Tristan, Nicolas de Prost, French m-TSS Study Group
doi : 10.1093/cid/ciab378
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Pages 246–253
Studies describing the clinical features and short-term prognosis of patients admitted to the intensive care unit (ICU) for menstrual toxic shock syndrome (m-TSS) are lacking.
Differential Cytokine Signatures of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Influenza Infection Highlight Key Differences in Pathobiology
Andrew H Karaba, Weiqiang Zhou, Leon L Hsieh, Alexis Figueroa, Guido Massaccesi, Richard E Rothman, Katherine Z J Fenstermacher, Lauren Sauer, Kathryn Shaw-Saliba, Paul W Blair, Matthew L Robinson, Sherry Leung, Russell Wesson, Nada Alachkar, Ramy El-Diwany, Hongkai Ji, Andrea L Cox
doi : 10.1093/cid/ciab376
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Pages 254–262
Several inflammatory cytokines are upregulated in severe coronavirus disease 2019 (COVID-19). We compared cytokines in COVID-19 versus influenza to define differentiating features of the inflammatory response to these pathogens and their association with severe disease. Because elevated body mass index (BMI) is a known risk factor for severe COVID-19, we examined the relationship of BMI to cytokines associated with severe disease.
Comparative 1-Year Outcomes of Invasive Staphylococcus aureus Infections Among Persons With and Without Drug Use: An Observational Cohort Study
Ayesha Appa, Meredith Adamo, Stephenie Le, Jennifer Davis, Lisa Winston, Sarah B Doernberg, Henry Chambers, Marlene Martin, Nancy K Hills, Phillip O Coffin, Vivek Jain
doi : 10.1093/cid/ciab367
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Pages 263–270
Persons who use drugs (PWUD) face substantial risk of Staphylococcus aureus infections. Limited data exist describing clinical and substance use characteristics of PWUD with invasive S. aureus infections or comparing treatment and mortality outcomes in PWUD vs non-PWUD. These are needed to inform optimal care for this marginalized population.
Retrospective Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Symptomatic Patients Prior to Widespread Diagnostic Testing in Southern California
Evann E Hilt, James Boocock, Marisol Trejo, Catherine Q Le, Longhua Guo, Yi Zhang, Laila Sathe, Valerie A Arboleda, Yi Yin, Joshua S Bloom, Pin-Chieh Wang, Joann G Elmore, Leonid Kruglyak, Lasata Shrestha, Shah A Mohamed Bakhash, Michelle Lin, Hong Xie, Meei-Li Huang, Pavitra Roychoudhury, Alexander Greninger, Sukantha Chandrasekaran, Shangxin Yang, Omai B Garner
doi : 10.1093/cid/ciab360
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Pages 271–277
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused one of the worst pandemics in recent history. Few reports have revealed that SARS-CoV-2 was spreading in the United States as early as the end of January. In this study, we aimed to determine if SARS-CoV-2 had been circulating in the Los Angeles (LA) area at a time when access to diagnostic testing for coronavirus disease 2019 (COVID-19) was severely limited.
Development and Validation of the Long Coronavirus Disease (COVID) Symptom and Impact Tools: A Set of Patient-Reported Instruments Constructed From Patients’ Lived Experience
Viet-Thi Tran, Carolina Riveros, Bérangère Clepier, Moïse Desvarieux, Camille Collet, Youri Yordanov, Philippe Ravaud
doi : 10.1093/cid/ciab352
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Pages 278–287
To develop and validate patient-reported instruments, based on patients’ lived experiences, for monitoring the symptoms and impact of long coronavirus disease (covid).
Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Kenya
Anthony O Etyang, Ruth Lucinde, Henry Karanja, Catherine Kalu, Daisy Mugo, James Nyagwange, John Gitonga, James Tuju, Perpetual Wanjiku, Angela Karani, Shadrack Mutua, Hosea Maroko, Eddy Nzomo, Eric Maitha, Evanson Kamuri, Thuranira Kaugiria, Justus Weru, Lucy B Ochola, Nelson Kilimo, Sande Charo, Namdala Emukule, Wycliffe Moracha, David Mukabi, Rosemary Okuku, Monicah Ogutu, Barrack Angujo, Mark Otiende, Christian Bottomley, Edward Otieno, Leonard Ndwiga, Amek Nyaguara, Shirine Voller, Charles N Agoti, David James Nokes, Lynette Isabella Ochola-Oyier, Rashid Aman, Patrick Amoth, Mercy Mwangangi, Kadondi Kasera, Wangari Ng’ang’a, Ifedayo M O Adetifa, E Wangeci Kagucia, Katherine Gallagher, Sophie Uyoga, Benjamin Tsofa, Edwine Barasa, Philip Bejon, J Anthony G Scott, Ambrose Agweyu, George M Warimwe
doi : 10.1093/cid/ciab346
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Pages 288–293
Few studies have assessed the seroprevalence of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among healthcare workers (HCWs) in Africa. We report findings from a survey among HCWs in 3 counties in Kenya.
Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients Undergoing Serial Laboratory Testing
Adnan I Qureshi, William I Baskett, Wei Huang, Iryna Lobanova, S Hasan Naqvi, Chi-Ren Shyu
doi : 10.1093/cid/ciab345
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Pages 294–300
A better understanding of reinfection after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become one of the healthcare priorities in the current pandemic. We determined the rate of reinfection, associated factors, and mortality during follow-up in a cohort of patients with SARS-CoV-2 infection.
Medium-Term Outcomes in Severely to Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Nandan Gautam, Shyam Madathil, Natascia Tahani, Shaun Bolton, Dhruv Parekh, James Stockley, Shraddha Goyal, Hannah Qureshi, Sadhika Yasmin, Brendan G Cooper, Jennifer Short, Tarekegn Geberhiwot
doi : 10.1093/cid/ciab341
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Pages 301–308
The medium- and long-term effects of severe acute respiratory syndrome coronavirus 2 infection on survivors are unknown. In the current study, we assessed the medium-term effects of coronavirus disease 2019 (COVID-19) on survivors of severe disease.
Mortality Trends in Risk Conditions and Invasive Mycotic Disease in the United States, 1999–2018
Emily Rayens, Karen A Norris, José F Cordero
doi : 10.1093/cid/ciab336
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Pages 309–318
Invasive fungal infections in the United States are chronically underdiagnosed and a lack of coordinated surveillance makes the true burden of disease difficult to determine. The purpose of this analysis was to capture mortality-associated burden of risk conditions and fungal infections.
Severe Acute Respiratory Syndrome Coronavirus 2 Transmission in a Georgia School District—United States, December 2020–January 2021
Jenna R Gettings, Jeremy A W Gold, Anne Kimball, Kaitlin Forsberg, Colleen Scott, Anna Uehara, Suxiang Tong, Marisa Hast, Megan R Swanson, Elana Morris, Emeka Oraka, Olivia Almendares, Ebony S Thomas, Lemlem Mehari, Jazmyn McCloud, Gurleen Roberts, Deanna Crosby, Abirami Balajee, Eleanor Burnett, Rebecca J Chancey, Peter Cook, Morgane Donadel, Catherine Espinosa, Mary E Evans, Katherine E Fleming-Dutra, Catalina Forero, Esther A Kukielka, Yan Li, Paula L Marcet, Kiren Mitruka, Jasmine Y Nakayama, Yoshinori Nakazawa, Michelle O’Hegarty, Caroline Pratt, Marion E Rice, Roxana M Rodriguez Stewart, Raquel Sabogal, Emanny Sanchez, Andres Velasco-Villa, Mark K Weng, Jing Zhang, Grant Rivera, Tonia Parrott, Rachel Franklin, Janet Memark, Cherie Drenzek, Aron J Hall, Hannah L Kirking, Jacqueline E Tate, Snigdha Vallabhaneni
doi : 10.1093/cid/ciab332
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Pages 319–326
To inform prevention strategies, we assessed the extent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission and settings in which transmission occurred in a Georgia public school district.
Impact of Convalescent Plasma Therapy on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Profile in Coronavirus Disease 2019 (COVID-19) Patients
Juanjie Tang, Gabrielle Grubbs, Youri Lee, Hana Golding, Surender Khurana
doi : 10.1093/cid/ciab317
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Pages 327–334
Convalescent plasma (CP) have been used for treatment of coronavirus disease 2019 (COVID-19), but their effectiveness varies significantly. Moreover, the impact of CP treatment on the composition of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in COVID-19 patients and antibody markers that differentiate between those who survive and those who succumb to the COVID-19 disease are not well understood.
Substantial Decline in Invasive Pneumococcal Disease During Coronavirus Disease 2019 Pandemic in Hong Kong
Jade L L Teng, Kenny M N Fok, Ken P K Lin, Elaine Chan, Yuanchao Ma, Susanna K P Lau, Patrick C Y Woo
doi : 10.1093/cid/ciab382
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Pages 335–338
Compared with other countries, a more substantial decrease in the incidence of invasive pneumococcal disease was observed in Hong Kong, which is most likely attributable to the proactive mass adoption of face masks by the public. Human behavioral changes, particularly mask wearing, should be considered as an additional preventive strategy against invasive pneumococcal disease.
Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a Patient Transport Van
Lucas D Jones, Ernest R Chan, Trina F Zabarsky, Jennifer L Cadnum, Maria E Navas, Sarah N Redmond, Jeffrey D Kovach, Marlin Linger, William A Rutala, Peter A Zimmerman, Curtis J Donskey
doi : 10.1093/cid/ciab347
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Pages 339–342
We report 2 episodes of potential SARS-CoV-2 transmission from infected van drivers to passengers despite masking and physical distancing. Whole-genome sequencing confirmed relatedness of driver and passenger SARS-CoV-2. With the heater operating, fluorescent microspheres were transported by airflow >3 meters from the front to the back of the van.
Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies Among Market and City Bus Depot Workers in Lima, Peru
Marco Tovar, Jes?s Peinado, Santiago Palomino, Fernando Llanos, Claudio Ram?rez, Gisella Valderrama, Roger I Calder?n, Roger B Williams, Gustavo E Vel?squez, Carole D Mitnick, Molly F Franke, Leonid Lecca
doi : 10.1093/cid/ciab323
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Pages 343–346
We report severe acute respiratory syndrome coronavirus 2 antibody positivity among market and city bus depot workers in Lima, Peru. Among 1285 vendors from 8 markets, prevalence ranged from 27% to 73%. Among 488 workers from 3 city bus depots, prevalence ranged from 11% to 47%. Self-reported symptoms were infrequent.
Premarket Development Times for Innovative Vaccines––To What Extent Are the Coronavirus Disease 2019 (COVID-19) Vaccines Outliers?
Reed F Beall, Aaron S Kesselheim, Aidan Hollis
doi : 10.1093/cid/ciab389
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Pages 347–351
One reason expressed in surveys of people reporting coronavirus disease 2019 (COVID-19) vaccine hesitancy is how rapidly these vaccines have reached the market.
Are Some COVID-19 Vaccines Better Than Others? Interpreting and Comparing Estimates of Efficacy in Vaccine Trials
Rekha R Rapaka, Elizabeth A Hammershaimb, Kathleen M Neuzil
doi : 10.1093/cid/ciab213
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Pages 352–358
Coronavirus disease 2019 (COVID-19) vaccine trials provide valuable insight into the safety and efficacy of vaccines, with individually randomized, placebo-controlled trials being the gold standard in trial design. However, a myriad of variables must be considered as clinical trial data are interpreted and used to guide policy decisions.
A Case of Persistent Aortic Graft and Retroperitoneal Enhancement on FDG PET/CT
Marwa Sabha, Anton Gryaznov, Romana Mayer, Allen Burke, James B Doub
doi : 10.1093/cid/ciab297
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Pages 359–362
Beware of Biases in Observational Studies on Anti-Spike Monoclonal Antibodies
Giuseppe Lapadula, Davide Paolo Bernasconi, Alessandro Soria, Maria Grazia Valsecchi, Paolo Bonfanti
doi : 10.1093/cid/ciab467
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Page 363
O-Antigen Targeted Vaccines Against Escherichia coli May Be Useful in Reducing Morbidity, Mortality, and Antimicrobial Resistance
Guilhem Royer, Olivier Clermont, Bénédicte Condamine, Mélanie Mercier-Darty, Cédric Laouénan, Agnès Lefort, Erick Denamur, Victoire de Lastours, COLIBAFI and SEPTICOLI Groups
doi : 10.1093/cid/ciab458
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Pages 364–366
Neutralization of Variant Under Investigation B.1.617.1 With Sera of BBV152 Vaccinees
Pragya D Yadav, Gajanan N Sapkal, Priya Abraham, Raches Ella, Gururaj Deshpande, Deepak Y Patil, Dimpal A Nyayanit, Nivedita Gupta, Rima R Sahay, Anita M Shete, Samiran Panda, Balram Bhargava, V Krishna Mohan
doi : 10.1093/cid/ciab411
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Pages 366–368
Is 3 Feet of Physical Distancing Enough?
Daniel A Harris, Mercedes Sobers, Zoë R Greenwald, Alison E Simmons, Jean-Paul R Soucy, Laura C Rosella
doi : 10.1093/cid/ciab439
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Pages 368–370
Reply to Author
Westyn Branch-Elliman, Rebecca S Jack, Elissa M Schechter-Perkins, Polly van den Berg, Isabella Epshtein, Emily Oster, Richard Nelson
doi : 10.1093/cid/ciab440
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Pages 370–371
Corrigendum to: Effectiveness of the 7- and 13-Valent Pneumococcal Conjugate Vaccines Against Vaccine-Serotype Otitis Media
Ron Dagan, Bart Adriaan Van Der Beek, Shalom Ben-Shimol, Tamara Pilishvili, Noga Givon-Lavi
doi : 10.1093/cid/ciab806
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Page 372
Erratum to: Deaths Attributable to Cancer in the US Human Immunodeficiency Virus Population During 2001–2015
Marie-Josèphe Horner, Meredith S Shiels, Ruth M Pfeiffer, Eric A Engels
doi : 10.1093/cid/ciab805
Clinical Infectious Diseases, Volume 74, Issue 2, 15 January 2022, Page 373
